The article incorrectly states that Cephalon's drug Sparlon is already approved for the treatment of wakefulness in adults and has been on the market in the United States for 7 years. The article should have stated that Cephalon's Provigil, which contains the same active ingredient (modafinil) as Sparlon but in different doses, is approved for the treatment of wakefulness in adults only and has been on the market in the United States for 9 years.
Additional information
The online version of the original article can be found at 10.1038/nrd2247
Rights and permissions
About this article
Cite this article
Owens, J. Erratum: 2006 drug approvals: finding the niche. Nat Rev Drug Discov 6, 252 (2007). https://doi.org/10.1038/nrd2282
Issue Date:
DOI: https://doi.org/10.1038/nrd2282
